ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
alnylam
The Director, Value & Evidence Strategy will lead real-world data analyses for late-stage and marketed biopharmaceutical assets, designing studies on treatment patterns, resource utilization, adherence, survival, and cost-effectiveness. The role collaborates with cross‑functional teams to develop payer‑facing analytic tools, economic models, and scientific communications, supporting the value proposition of rare disease therapies.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
13% above the average for this role
Associate, Evidence Synthesis
Medicus Economics
Director, Value and Evidence
Rhythm Pharmaceuticals
Manager, Health Economics & Payer Evidence (HEPE)
AstraZeneca
Senior Manager, Payer Evidence, Methods, & Access Affairs
AstraZeneca
Director, HEOR & Value Evidence
Telix Pharmaceuticals
Executive Director, Health Economics & Outcomes Research (HEOR), Global Medical Affairs
Zenas BioPharma